What are you prescribing for atrial fibrillation?

Dr Aajuli Shukla

writer

Dr Aajuli Shukla

General Practitioner; Deputy Medical Editor, Medical Journal of Australia; Member of the Editorial Advisory Board for the Diabetes Management Journal

Dr Aajuli Shukla

 

Despite the widespread uptake of DOACs, they are still underutilised and atrial fibrillation is still undertreated in Australia.

This is according to Dr Andrew Sindone, Cardiologist and Director of the Heart Failure Unit and Department of Cardiac Rehabilitation at Concord Hospital, New South Wales.

“The general practitioner is the gatekeeper. They are often the ones who detect it [atrial fibrillation], or suspect it, and either treat it or refer on.”

PASSWORD RESET

Forgot your password or password not working? Please enter your email address. You will receive an email with the link to set a new password.

References

1 Figure 1 of the paper. https://doi.org/10.1016/j.hlc.2018.03.010

2 “Australians with non-valvular atrial fibrillation are currently using NOACs in preference to warfarin at a ratio of 2:1.”
https://doi.org/10.1016/j.hlc.2018.03.010

3 In this nationwide cohort study of patients ≥75 years initiating oral anticoagulation for AF, standard and reduced dose NOACs were associated with similar risks of stroke/SE as warfarin and lower or similar risks of bleeding. The NOACs seem to be a safe option also in elderly patients. https://heart.bmj.com/content/108/5/345

4 The use of DOACs is a reasonable alternative to vitamin K antagonists in AF patients with CHADS2 score ≥3, advanced age, and HF. The RI constitutes a useful, additional tool to facilitate clinicians in choosing DOACs or warfarin in particular category of AF patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761253/

5 “Warfarin was associated with a greater decline in eGFR than either low-dose (HR: 0.81, 95% CI: 0.69–0.96) or standard-dose dabigatran (HR: 0.79, 95% CI: 0.68–0.93), whereas apixaban showed a similar risk of acute renal failure compared with warfarin in ARISTOTLE trial (RR: 0.97, 95% CI: 0.88–1.07)” https://journals.lww.com/md-journal/Fulltext/2019/11290/The_impact_of_renal_function_on_efficacy_and.87.aspx

6 However, mechanical heart valves currently pose an absolute contraindication to NOACs based on the results of a single phase II study comparing dabigatran and warfarin (RE-ALIGN [Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients after Heart Valve Replacement]). That trial was stopped prematurely because of an excess of both stroke and bleeding with the dabigatran doses tested https://doi.org/10.1161/CIRCULATIONAHA.118.035612

7 Individual state government sites and also this article from RACGP https://www.racgp.org.au/afp/2014/may/anticoagulation

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Richard Bradlow

Dr Richard Bradlow

Alcohol Addiction Assessment and Advice

Prof Rodney Baber AM

Prof Rodney Baber AM

Premature Ovarian Insufficiency – The New Guidelines

Dr Sam Mehr

Dr Sam Mehr

Paediatric Allergic Rhinitis & Immunotherapy

Dr Andrew Scroop

Dr Andrew Scroop

Inhaler Devices

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Share this

Share this

Dr Aajuli Shukla

writer

Dr Aajuli Shukla

General Practitioner; Deputy Medical Editor, Medical Journal of Australia; Member of the Editorial Advisory Board for the Diabetes Management Journal

Test your knowledge

Recent articles

Latest GP poll

What impact do you think publishing fee data will have on the cost to patients to see a GP?

Increase

0%

No change

0%

Decrease

0%

Find your area of interest

Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.

Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.

Webcast TONIGHT

POTS – What You Need to Know

Tuesday 17th February, 7pm - 9pm AEDT

Speaker

Prof Dennis Lau

Cardiac Electrophysiologist; The Royal Adelaide Hospital; Clinical Professor, The University of Adelaide

Hear the latest evidence-based management options for POTS - a common, yet poorly recognised and misunderstood autonomic dysfunction condition in our community. Join Prof Dennis Lau for an update on POTS, who is at risk, presenting symptoms and how it can be diagnosed in the primary care setting.